BCRX - BIOCRYST PHARMACEUTICALS INC
IEX Last Trade
7.7
0.030 0.390%
Share volume: 17,703
Last Updated: Fri 27 Dec 2024 08:30:01 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$7.67
0.03
0.39%
Fundamental analysis
37%
Profitability
47%
Dept financing
26%
Liquidity
70%
Performance
22%
Performance
5 Days
-0.77%
1 Month
2.93%
3 Months
1.31%
6 Months
26.35%
1 Year
24.72%
2 Year
-29.30%
Key data
Stock price
$7.70
DAY RANGE
$7.59 - $7.78
52 WEEK RANGE
$4.17 - $8.88
52 WEEK CHANGE
$28.88
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Jon P. Stonehouse
Region: US
Website: biocryst.com
Employees: 530
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: biocryst.com
Employees: 530
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
BioCryst Pharmaceuticals, Inc. discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases. Galidesivir, a RNA dependent-RNA polymerase inhibitor, is in clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola,
Recent news